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We estimate that around 2000 infants in Uganda
develop hydrocephalus (HC) each year. Post-infectious
hydrocephalus (PIH) accounts for 60% of all cases, and
several lines of investigation are underway to determine
the pathogens and their mode of transmission. HC asso-
ciated with myelomeningocele (MM) is the second most
common etiology, accounting for 15% of cases.
Access to treatment for hydrocephalus in Africa is
inhibited by poverty, politics, poor infrastructure, and a
paucity of neurosurgeons. These also present obstacles
to follow up and emergency care for treatment failure,
making death from future shunt malfunction a serious
enduring threat.
We explored the role of endoscopic treatment for
hydrocephalus in African infants, and found that com-
bined endoscopic third ventriculostomy and bilateral
choroid plexus cauterization (ETV/CPC) was signifi-
cantly more successful than ETV alone in those less
than one year of age. Infants with myelomeningocele
benefitted the most from this approach, with a 76% suc-
cess rate. In contrast to shunt failure, nearly all ETV/
CPC failures become evident within 6 months of sur-
gery. We have demonstrated factors that are indepen-
dently predictive of ETV/CPC outcome, and have
generated a new outcome prediction score (the Uganda
Score) that is currently being evaluated across several
centers in Africa.
In addition to safety and long-term efficacy of ETV/
CPC in the myelomeningocele population, we also
demonstrated that those treated in this way performed as
well or better on the Bayley Scales of Infant Development
over the course of their early childhood development
than those who were shunted. Furthermore, we found no
correlation between performance and ventricle size. We
recently investigated whether the presence of HC or its
method of treatment affected 5 year survival in these
children, and were surprised to find no difference. Impor-
tantly, the most important determinant of survival was
involvement in a community-based rehabilitation pro-
gram. The five year mortality for these children was close
to that of their unaffected peers (16%); whereas the mor-
tality for those with no access to such a program was
more than triple (50%). Deaths were mostly from causes
not directly related to the underlying neurological
conditions.
ETV/CPC is a safe and effective alternative to shunt-
dependence in children with myelomeningocele. In Africa,
any long-term survival advantage of shunt-independence
may be obscured by diseases of poverty and neglect. “Life-
saving surgery” in these children must be wedded to com-
munity-based support programs that promote their access
to adequate health care and nutrition.
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